AD

COOPERATIVE AGREEMENT NO: DAMD17-93-V-3008

TITLE: AUTORADIOGRAPHIC DISTRIBUTION AND APPLIED PHARMACOLOGICAL CHARACTERISTICS OF DEXTROMETHORPHAN AND RELATED ANTITISSUE/ANTICONVULSANT DRUGS AND NOVEL ANALOGS

SUBTITLE: Autoradiographical Distribution of ³H-Dextromethorphan Binding Sites in Rat and Human Brain

PRINCIPAL INVESTIGATOR: Professor Norman G. Bowery

CONTRACTING ORGANIZATION:

University of London Department of Pharmacology The School of Pharmacy 29/39 Brunswick Square London WCIN 1AX, England

REPORT DATE: October 1, 1994

TYPE OF REPORT: Midterm Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

19950112 019

Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DER QUALTEY RESPECTED 3

ſ

IAN 1

REPORT D	DOCUMENTATION PA	AGE	Form Approved OMB No. 0704-0188
Public reporting burden for this collection of gathering and maintaining the data needed, a collection of information, including suggestio Davis Highway, Suite 1204, Arlington, VA 222	information is estimated to average 1 hour per r and completing and reviewing the collection of ir ins for reducing this burden. to Washington Hea 202-4302, and to the Office of Management and I	response, including the time for re nformation. Send comments regard dquarters Services, Directorate for Budget, Paperwork Reduction Proj	viewing instructions, searching existing data sources ding this burden estimate or any other aspect of thi Information Operations and Reports, 1215 Jeffersor ect (0704-0188), Washington, DC 20503.
1. AGENCY USE ONLY (Leave bla	ank) 2. REPORT DATE	3. REPORT TYPE ANI	D DATES COVERED
	October 1, 1994	Midterm Repo	r + (9/27/93 - 9/26/94)
4. TITLE AND SUBTITLE AUTON	radiographic Distri	bution and	5. FUNDING NUMBERS
Applied Pharmacolo	ogical Characterist	ics of Dextro-	
methorphan and rel	lated Antitissue/An	ticonvulsant	Cooperative Agreeme
Drugs and Novel Ar	nalogs		DAMD17-93-V-3008
6. AUTHOR(S)	· · ·		
Norman G. Bowery,	P. Meoni, K.A. Beva	an	
PERFORMING ORGANIZATION	NAME(S) AND ADDRESS(ES)		8 PERFORMING ORGANIZATION
University of Lond	lon		REPORT NUMBER
Department of Phar	cmacology		
The School of Phar	cmacy		
29/39 Brunswick Sc	luare		
London WCIN 1AX, F	Ingland		
. SPONSORING / MONITORING AC	GENCY NAME(S) AND ADDRESS(ES)		10. SPONSORING / MONITORING
U.S. Army Medical	Research and Mater:	iel Command	
Fort Detrick			
Frederick, Marylan	nd 21/02-5012		
11. SUPPLEMENTARY NOTES			
2a. DISTRIBUTION / AVAILABILITY Approved for publi	STATEMENT c release; distribu	ution unlimite	12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 woi	rds) ,		
Dextromethorphan j	is an antitussive compound	with anticonvulsan	t and neuroprotective properti
arising from actions	within the central nervous	system of mammals	s. In the present study we ha
determined the distri	ibution of [³ H]-dextromethor	phan ([³ H]-DM) bin	ding sites in normal rat brain a
72 hours after middl	e cerebral artery occlusion.	The pattern of distri	bution did not correlate with th
of the excitatory ami	no acid, N-methyl-D-asparta	te (NMDA), with wh	nich an association has previous
been suggested on 1	the basis of a weak pharma	cological interaction	A decrease in binding with
certain regions of th	e cerebral cortex of occlude	d animals was obser	rved. However, this was limit
and may be a conse	quence of the possible intrac	cellular location of the	he DM sites or simply due to t
period allowed betw	een the occlusion and prepar	ring the brain section	s. At 72 hours [³ H]-DM bindi
was clearly not a m	arker for the degree of neur	onal damage. At a	itoradiographic technique is a
haing daysland for			
	examining the binding of $[^3$	HI-DM in post mor	tem human whole brain section
Whole coronal sect	examining the binding of [³ ions have been prepared an	H]-DM in post mort d binding of [³ H]-I	tem human whole brain section DM obtained. However, furth
Whole coronal sect	examining the binding of [³ ions have been prepared an es are required to obtain the	H]-DM in post mort d binding of [³ H]-I optimal conditions for	tem human whole brain section DM obtained. However, furth or obtaining a distribution patter
Whole coronal sect developmental studie of [³ H]-DM sites	examining the binding of [³ ions have been prepared an es are required to obtain the	H]-DM in post more ad binding of [³ H]-I optimal conditions for	tem human whole brain section DM obtained. However, furth or obtaining a distribution patte
Whole coronal sect developmental studio of [³ H1-DM sites. 4. SUBJECT TERMS	examining the binding of [³ ions have been prepared an es are required to obtain the	H]-DM in post mort d binding of [³ H]-I optimal conditions fe	tem human whole brain section DM obtained. However, furth or obtaining a distribution patter 15. NUMBER OF PAGES
Whole coronal sect developmental studi of [³ Hl-DM sites. 4. SUBJECT TERMS Drugs, Anticonvuls	examining the binding of [³ ions have been prepared an es are required to obtain the ants, Neuroprotecti	H]-DM in post mort d binding of [³ H]-I optimal conditions for twe, Dextromet	tem human whole brain section DM obtained. However, furth or obtaining a distribution patter 15. NUMBER OF PAGES horphan
Whole coronal sect developmental studi of [³ Hl-DM sites. 4. SUBJECT TERMS Drugs, Anticonvuls utoradiography, R	examining the binding of [³ ions have been prepared an es are required to obtain the ants, Neuroprotection AD V, RAD II	H]-DM in post mort ad binding of [³ H]-I optimal conditions fo 	tem human whole brain section DM obtained. However, furth or obtaining a distribution patte 15. NUMBER OF PAGES horphan, 16. PRICE CODE
Whole coronal sect developmental studie of [³ Hl-DM sites. 4. SUBJECT TERMS Drugs, Anticonvuls Autoradiography, R 7. SECURITY CLASSIFICATION OF REPORT	examining the binding of [³ ions have been prepared an es are required to obtain the ants, Neuroprotection AD V, RAD II 18. SECURITY CLASSIFICATION OF THIS PAGE	H]-DM in post mort d binding of [³ H]-I optimal conditions for twe, Dextromet ^{19. SECURITY CLASSIFIC OF ABSTRACT}	tem human whole brain section DM obtained. However, furth or obtaining a distribution patter 15. NUMBER OF PAGES horphan, 16. PRICE CODE ATION 20. LIMITATION OF ABSTRAC

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Acces	ion For		
NTIS DTIC Unann Justifi	CRA&I TAB iounced cation		
By Distribution /			
Availability Codes			
Dist	Avail and/or Special		
A-1			- 1

241

ij

<u>AUTORADIOGRAPHICAL DISTRIBUTION OF ³H-DEXTROMETHORPHAN</u> <u>BINDING SITES IN RAT AND HUMAN BRAIN</u>

Introduction

Dextromethorphan (DM) is a non-opioid cough suppressant which is the dextrorotatory isomer of the opioid levorphanol. However, it exhibits little or none of the actions of the opioids with no analgesic activity or respiratory depressant activity. Binding sites for radiolabelled dextromethorphan have been demonstrated in rat, guinea-pig and mouse brain and these sites are distinct from opiate receptors and, in particular, are not recognised by the competitive opiate antagonist, naloxone. However, the physiological relevance of these DM binding sites has still to be fully established although it is tempting to speculate that they are associated with the anticonvulsant and neuroprotective activities of DM. It seems plausible that activation of these binding sites mediates these pharmacological effects possibly via modulation of a voltage-operated calcium channel although a weak link with excitatory amino acid N-methyl-D-aspartate (NMDA) -gated channels has been proposed.

The purpose of the present study, which is continuing, is to examine fully the distribution of DM binding sites in normal rat brain and following ischaemic damage produced by middle cerebral artery occlusion. In addition, a full analysis of the distribution of these sites in post mortem human whole brain sections is underway although development of the technique in human brain tissue is still at an early stage.

Methods

[³H]-Dextromethorphan receptor autoradiography - rat brain

Rats (Sprague-Dawley) were sacrificed by cervical dislocation and decapitation and the brains rapidly removed and frozen by immersion in isopentane cooled in liquid nitrogen. Frozen brains were stored at -80°C and subsequently equilibrated at -20°C for preparing cryostat sections (10-20µm). Each section was thaw-mounted on a glass slide previously coated with a solution of gelatine (0.5%) and chromic potassium sulphate (0.05%) in water (5 minutes immersion followed by drying in a stream of warm air). Slide-mounted sections were stored at -20°C until required. Thawed sections were immersed in buffer solution (Tris-HCl 50mM pH 7.5 or phosphate buffer pH 7.5 or Krebs' solution) at room temperature for 30 minutes and then allowed to dry. 350-500µl of buffer solution (normally Tris-HCl unless specified) containing 25nM [³H]-dextromethorphan (83 Ci/mmol) was pipetted on to each slide to cover the brain section. For determining non-specific binding 100µM unlabelled DM was also present. The sections were incubated at room temperature or 4°C for 30 minutes unless otherwise stated. After incubation the solution was

aspirated off and the slides washed three times for 5 minutes in ice-cold buffer before drying under a stream of cool air. Dry slides were juxtaposed to tritium-sensitive film (Hyperfilm) for approximately 30 days before developing the film in D-19 developer. Films were analysed by Quantimet image analysis to determine the amount of radiolabelled DM bound to each section. Calibration standards on each film enabled a quantitative analysis to be made. As a preliminary to determine the conditions most suitable for obtaining optimal binding, sections were immersed in scintillation fluid and radioactivity levels determined in a scintillation spectrometer. Subsequently this also provided an indication of the length of time required for exposure of each film.

[³H]-Dextromethorphan receptor autoradiography - human brain

Normal whole brains were obtained with a full history of each individual. Brains were sliced coronally at 1.5cm intervals whilst frozen at -20°C. Experiments performed so far, have employed 1-2cm square 30-40µm sections of cerebral cortex to provide the optimal conditions for binding. These experiments are still in progress. At the same time we have been developing a method for preparing whole brain sections to perform the autoradiographical analysis of [³H]-DM binding. Coronal slabs of brain (1.5cm thick) are supported in a viscous solution of carboxy-methyl cellulose and frozen at -20°C. This frozen slab is then mounted on the stage of a PMV microtome for preparing 30-40µm sections. Fig.1a illustrates this arrangement where the brain block can be seen below and to the right of the knife-holder. Sections are cut at -20°C and mounted on a Hydrobond support membrane in preparation for incubation with [³H]-DM. A section just obtained from the cryostat is shown in Fig.1b This section of frontal cortex is being held by hand to provide an indication of the size of the tissue. This is then dried and incubated by immersion in a solution containing [³H]-DM. Preliminary data indicate that specific binding can be obtained in human brain but the ideal conditions have yet to be established. Using the incubation conditions established for rat brain sections has provided the starting point. However, the nature of the incubation buffer to be used has yet to be fixed as preliminary data indicate that the degree of specific binding differs depending on the buffer solution employed (see Fig.2). The maximal specific binding obtaining thus far is 23% of total which must be increased before attempting autoradiographic imaging. Further results are, therefore, not included in this report.

Autoradiography in brain sections from rats subjected to middle cerebral artery occlusion Surgical Procedure

Male Sprague-Dawley rats (200-350g) were maintained on a 12 hour light/dark cycle and allowed access to food and water *ad libitum* both before and after the surgical procedure.

Rats were anaesthetised intraperitoneally with 60mgkg⁻¹ sodium pentobarbitone and placed in a supine position on a heated operating table. The left and right common carotid arteries were exposed through a 1mm incision made in the midline of the neck and the vagal nerve carefully teased away from the blood vessels. A ligature was then placed loosely around each vessel.

The rat was then turned on its left side, and a 2cm vertical incision made midway between the right eye and right ear, taking care to avoid transection of the facial nerve. The temporalis muscle was cut with entomological scissors and watchmakers forceps in a manner to protect against traumatisation and bleeding of the tissue. The zygomatic arch and squamosal bone of the skull were then exposed under low power of the stereomicroscope (Zeiss Instruments). Using a saline-cooled dental drill, the exposed skull was removed to a thin layer above the middle cerebral artery. This layer was carefully peeled away using watchmakers forceps, leaving the middle cerebral artery clearly visible through the dura and arachnoid mater. At this point, the common carotid arteries were occluded; the right artery was permanently ligated, and the left artery occluded, using a small artery clip, for 60 minutes.

Using the tip of a fine needle and watchmakers forceps, the dura was carefully lifted away from the brain and cut to expose the middle cerebral artery. The surface of the brain was kept moistened with saline at all times. The arachnoid was parted and the middle cerebral artery was lifted slightly from the brain using the fine needle, and coagulated by passing an electric current (50mA) through the tips of microforceps placed along either side along a predetermined length of the vessel, for approximately 1-2mm below the level of the inferior cerebral vein. The artery was then cut to ensure complete occlusion. All visible branches of the middle cerebral artery were also occluded. The temporalis muscle was sutured separately from the overlying skin layers, and the wound cleaned up and treated with "Cicatrin" powder (antibacterial) and Xylocaine spray (local anaesthetic). In sham-operated animals, exactly the same procedure was followed, except that the dura was opened over the artery, but the artery was not occluded.

The rats were placed in an incubator at 32°C to maintain body temperature until recovery from anaesthesia was complete (usually within 2 hours). Temperature was monitored throughout the experiment, and maintained via adjustment of the heated table between 37.5°C and 38.5°C. Once recovery from anaesthesia was complete, the animals were returned to their cages, and maintained as described above. Body weight was monitored every 24 hours from the day of the experiment to the day of sacrifice.

The rats were sacrificed at 72 hours when the extent of neural damage in other rats had been fully determined by triphenyltetrazolium chloride staining. The brains were removed and frozen at -80°C for at least 24 hours. Sections (20µm) were cut at -20°C and the distribution of [³H]-DM binding sites in the ipsilateral and contralateral sides of the brain determined as described above. Comparison with sham-operated as well as normal control rats was made.

<u>Results</u> - Rat brain

Effect of incubation time on ³H-DM binding

The influence of the incubation time at room temperature (RT) and 4° C on ³H-DM binding is illustrated in Fig.3 and Fig.4 In these experiments the wash time was fixed at 15 minutes (3 x 5 minutes). Comparable results were obtained at the two temperatures although the rate of association was, not surprisingly, faster at room temperature that at 4° C. However, equilibration was achieved in both cases by 30 minutes with at least 50% specific binding being obtaining throughout the incubation period.

Influence of washing time

The dissociation of ³H-DM from sections of rat brain, by washing the sections for periods up to 60 minutes, is illustrated in Fig.5 This indicates the femtomoles of ³H-DM specifically bound to whole parasaggital sections of rat brain (approx. 0.5mm from midline) after washing for 2.5, 5, 10, 15, 30 and 60 minutes in Tris HCl buffer at 4°C. The percentage specific binding at each time point is shown in the inset. Although the amount bound rapidly decreased the proportion specifically bound increased after 5 minutes. Thus, a 15 minute washing time was chosen for all subsequent studies.

Autoradiographical distribution of [³H]-DM binding sites in rat brain

The distribution of [³]-DM in normal rat brain is shown in Table 1. In general, binding was highest in the midbrain, hindbrain and the molecular cerebellar layer. High levels of [³H]-DM binding were found in the dorsal raphe, rhabdoid nucleus and Purkinje cell layer of the cerebellum, while low levels were found in the olfactory bulb, thalamus, hypothalamus and the cerebellar molecular layer. Binding was high in the anterior amygdaloid nuclei, but was considerably lower in the medial basolateral amygdaloid nucleus. Intermediate levels of binding were found throughout the cortex of the brain, the striatum, hippocampus (CA1, CA2, CA3 regions, dentate gyrus) lateral geniculate nucleus and various structures of the midbrain (substantia nigra and tegmental nucleus), pons (pontine nucleus, locus coeruleus), and the granule cell layer

of the cerebellum. In the brain stem, binding was concentrated in the spinal trigeminal nucleus, but was very low in the spinal trigeminal tract.

Distribution of [³H]-DM sites in rat brain following middle cerebral artery occlusion

Fig.6 illustrates the extent of the infarct in rat brain 72 hours after middle cerebral artery occlusion. The mean (\pm s.e.m.) area of the infarct was $61.0 \pm 4.6 \text{ mm}^2$ in 6 rats which contrasted with 40.1 \pm 2.9 after 24 hours (n=6). At 48 hours and 96 hours the areas were not significantly different (54.0 \pm 6.9; n=7 and 55.6 \pm 4.4; n=5, respectively) from the 72 hour value.

Tables 2 & 3 show the comparative densities of [³H]-DM binding sites in sham-operated and middle cerebral artery occluded rat brain sections following incubation in 25nM [³H]-DM. A reduced density of binding on the ipsilateral side of the occluded brains was noted particularly in the parietal cortex although a possible reduction was also apparent in other cortical regions. There were no obvious changes in the cingulate, frontal or entorhinal cortices and many other brain regions including the nucleus accumbens, globus pallidus, amygdala and lateral geniculate. Overall little or no changes in binding occurred in regions outside the infarct region. Presumably the reductions which did occur reflect the necrosis of cells in those regions. However, the loss of binding was not as great as might be expected in those regions if the binding is simply a marker of neuronal integrity. It seems possible that DM may bind to an intracellular component of neurones i.e. microsomal rather than the synaptosomal fraction to which most neurotransmitter binding occurs. Perhaps cellular necrosis does not alter this, at least within the 72 hour period studied so far.

As mentioned in the Introduction, it has been suggested that there may be a functional relationship between DM sites and the NMDA receptor. However, the distribution of [³H]-DM binding sites observed in the present study do not correlate with the known distribution of NMDA binding sites. This does not rule out the existence of a functional interaction between DM and NMDA in discrete regions of the brain but it does support the view that DM can exert its effects independently of the NMDA receptor complex.

In summary, we have defined the distribution of binding sites for DM in the normal rat brain as well as in brains obtained from animals 2 hours after middle cerebral artery occlusion. The occlusion had only limited influence on the overall distribution of binding sites. A technique for examining the distribution of [³H]-DM binding sites in post mortem human whole brain sections has been developed and future studies will be devoted to establishing the pattern of binding in both normal and diseased brains.

Area	[³ H]-DM Bound (fmol/mg tissue)	n
Olfactory bulb:		
Olfactory bulb	18.8 ± 3.0	4
AOD	19.8 ± 2.8	4
Cerebral Cortex:		
cingulate	38.6 ± 9.7	4
frontal	36.3 ± 6.8	4
parietal	37.6 ± 8.5	4
insular	40.0 ± 5.1	4
piriform	39.8 ± 4.8	4
retrosplenial	41.4 ± 8.8	4
occipital	38.2 ± 6.8	4
temporal	37.2 ± 7.8	4
perirhinal	35.6 ± 10.1	4
entorhinal	30.1 ± 6.7	4
Basal Ganglia:		
caudate putamen	35.1 ± 6.8	4
nucleus acumbens	40.3 ± 7.3	4
globus pallidus	41.9 ± 11.6	4
Septum:		
lateral septal nucleus	33.2 ± 5.2	4
Amvedala:		
anterior amygdaloid nucleus	45.6 ± 10.8	4
basolateral amygdaloid nucleus	20.3 ± 3.7	4
Hippocampus		
CA1	305 ± 0.7	
CA2	39.3 ± 9.7	
CA3	44.2 + 8.6	
dentate gyrus	43.2 ± 0.0 43.2 ± 11.9	4
Thalamus		
ventromedial thalamus	298 ± 56	
laterodorsal thalamus	27.0 ± 3.0 28.4 ± 5.2	4
lateral geniculate nucleus	20.4 ± 3.2	4
8	47.4 1 0.0	4
Hypothalamus:		
ventromedial hypothalamus	21.8 ± 3.7	4

TABLE 1Autoradiographical distribution of [³H]-DM binding sites in rat brain

TABLE 1 (continued)

Midbrain: central grey57.5 \pm 10.54Midbrain: central grey57.5 \pm 10.54superior colliculus54.9 \pm 15.64inferior colliculus32.8 \pm 11.94caudal linear raphe nucleus49.4 \pm 8.54dorsal raphe nucleus72.4 \pm 28.94median raphe nucleus53.8 \pm 27.24rhaboid nucleus62.7 \pm 11.44interpeduncular nucleus50.1 \pm 9.14substantia nigra48.5 \pm 13.24Cranial Nerve Nuclei: spinal trigeminal nuclei55.3 \pm 11.14pontine nucleus35.1 \pm 3.44locus coeruleus42.4 \pm 3.44dorsal tegmental nuclei42.7 \pm 12.24raphe points37.4 \pm 13.64Medulla Oblongata: nucleus solitary tract brainstem reticular nucleus48.5 \pm 9.54Cerebellum:44.2 \pm 4.44	Δ reg	[³ H]-DM Bound (fmol/mg tissue)	n
Midbrain: central grey 57.5 ± 10.5 4superior colliculus 54.9 ± 15.6 4inferior colliculus 32.8 ± 11.9 4caudal linear raphe nucleus 49.4 ± 8.5 4dorsal raphe nucleus 72.4 ± 28.9 4median raphe nucleus 62.7 ± 11.4 4interpeduncular nucleus 62.7 ± 11.4 4interpeduncular nucleus 50.1 ± 9.1 4substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei: spinal trigeminal nucleispinal trigeminal nuclei 55.3 ± 11.1 4orss: pontine nucleus 42.4 ± 3.4 4dorsal tegmental nuclei 42.7 ± 12.2 4Adorsal tegmental nuclei 42.7 ± 13.6 4Medulla Oblongata: 		(Intol/ing tissue)	11
central grey 57.5 ± 10.5 4superior colliculus 54.9 ± 15.6 4inferior colliculus 32.8 ± 11.9 4caudal linear raphe nucleus 49.4 ± 8.5 4dorsal raphe nucleus 72.4 ± 28.9 4median raphe nucleus 53.8 ± 27.2 4rhaboid nucleus 62.7 ± 11.4 4interpeduncular nucleus 50.1 ± 9.1 4substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei: 55.3 ± 11.1 4spinal trigeminal nuclei 55.3 ± 11.1 4pontine nucleus 42.4 ± 3.4 4locus coeruleus 35.1 ± 3.4 4dorsal tegmental nuclei 42.7 ± 12.2 4raphe points 37.4 ± 13.6 4Medulla Oblongata: 48.5 ± 9.5 4nucleus solitary tract 48.5 ± 9.5 4brainstem reticular nucleus 53.7 ± 13.0 4inferior olive 48.2 ± 4.4 4Cerebellum: 48.2 ± 4.4 4	Midbrain:		
superior colliculus 54.9 ± 15.6 4inferior colliculus 32.8 ± 11.9 4caudal linear raphe nucleus 49.4 ± 8.5 4dorsal raphe nucleus 72.4 ± 28.9 4median raphe nucleus 53.8 ± 27.2 4rhaboid nucleus 62.7 ± 11.4 4interpeduncular nucleus 50.1 ± 9.1 4substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei: 55.3 ± 11.1 4spinal trigeminal nuclei 55.3 ± 11.1 4pontine nucleus 42.4 ± 3.4 4locus coeruleus 35.1 ± 3.4 4dorsal tegmental nuclei 37.4 ± 13.6 4Medulla Oblongata: 72.4 ± 9.5 4nucleus solitary tract 48.5 ± 9.5 4brainstem reticular nucleus 53.7 ± 13.0 4erebellum: 48.2 ± 4.4 4	central grey	57.5 \pm 10.5	4
inferior colliculus 32.8 ± 11.9 4caudal linear raphe nucleus 49.4 ± 8.5 4dorsal raphe nucleus 72.4 ± 28.9 4median raphe nucleus 53.8 ± 27.2 4rhaboid nucleus 62.7 ± 11.4 4interpeduncular nucleus 62.7 ± 11.4 4substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei: 55.3 ± 11.1 4spinal trigeminal nuclei 55.3 ± 11.1 4spinal trigeminal nuclei 55.3 ± 11.1 4pontine nucleus 42.4 ± 3.4 4locus coeruleus 35.1 ± 3.4 4dorsal tegmental nuclei 42.7 ± 12.2 4raphe points 37.4 ± 13.6 4Medulla Oblongata: 48.5 ± 9.5 4nucleus solitary tract 48.5 ± 9.5 4brainstem reticular nucleus 53.7 ± 13.0 4inferior olive 48.2 ± 4.4 4	superior colliculus	54.9 ± 15.6	4
caudal linear raphe nucleus 49.4 ± 8.5 4dorsal raphe nucleus 72.4 ± 28.9 4median raphe nucleus 53.8 ± 27.2 4rhaboid nucleus 62.7 ± 11.4 4interpeduncular nucleus 50.1 ± 9.1 4substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei:spinal trigeminal nuclei 55.3 ± 11.1 4spinal trigeminal nuclei 55.3 ± 11.1 4pontine nucleus 20.3 ± 2.6 4Pons: 42.4 ± 3.4 4dorsal tegmental nuclei 42.7 ± 12.2 4araphe points 37.4 ± 13.6 4Medulla Oblongata: nucleus solitary tract 48.5 ± 9.5 4brainstem reticular nucleus inferior olive 53.7 ± 13.0 4Cerebellum: 42.4 ± 4.4 4	inferior colliculus	32.8 ± 11.9	4
dorsal raphe nucleus 72.4 ± 28.9 4median raphe nucleus 53.8 ± 27.2 4rhaboid nucleus 62.7 ± 11.4 4interpeduncular nucleus 50.1 ± 9.1 4substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei:spinal trigeminal nuclei 55.3 ± 11.1 4spinal trigeminal nuclei 55.3 ± 11.1 4pontine nucleus 20.3 ± 2.6 4Pons: 42.4 ± 3.4 4dorsal tegmental nuclei 42.7 ± 12.2 4araphe points 37.4 ± 13.6 4Medulla Oblongata: 48.5 ± 9.5 4inferior olive 48.2 ± 4.4 4Cerebellum:	caudal linear raphe nucleus	49.4 ± 8.5	4
median raphe nucleus rhaboid nucleus interpeduncular nucleus substantia nigra 53.8 ± 27.2 62.7 ± 11.4 4 50.1 ± 9.1 48.5 ± 13.2 4 Cranial Nerve Nuclei: spinal trigeminal nuclei spinal trigeminal tract 55.3 ± 11.1 20.3 ± 2.6 4 Pons: pontine nucleus locus coeruleus dorsal tegmental nuclei raphe points 42.4 ± 3.4 42.7 ± 12.2 37.4 ± 13.6 4 Medulla Oblongata: nucleus solitary tract brainstem reticular nucleus inferior olive 48.5 ± 9.5 53.7 ± 13.0 48.2 ± 4.4 4 Cerebellum: Delivit: 42.4 ± 3.4 44.4 4	dorsal raphe nucleus	72.4 ± 28.9	4
rhaboid nucleus 62.7 ± 11.4 4interpeduncular nucleus 50.1 ± 9.1 4substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei: 55.3 ± 11.1 4spinal trigeminal nuclei 55.3 ± 11.1 4spinal trigeminal tract 20.3 ± 2.6 4Pons: 42.4 ± 3.4 4locus coeruleus 42.7 ± 12.2 4dorsal tegmental nuclei 37.4 ± 13.6 4Medulla Oblongata: 37.4 ± 13.0 4inferior olive 48.5 ± 9.5 4Cerebellum: 48.2 ± 4.4 4	median raphe nucleus	53.8 ± 27.2	4
interpeduncular nucleus 50.1 ± 9.1 4substantia nigra 48.5 ± 13.2 4 Cranial Nerve Nuclei: 55.3 ± 11.1 4 spinal trigeminal nuclei 55.3 ± 11.1 4 spinal trigeminal tract 20.3 ± 2.6 4 Pons: 20.3 ± 2.6 4 pontine nucleus 42.4 ± 3.4 4 locus coeruleus 35.1 ± 3.4 4 dorsal tegmental nuclei 42.7 ± 12.2 4 raphe points 37.4 ± 13.6 4 Medulla Oblongata: 48.5 ± 9.5 4 inferior olive 48.2 ± 4.4 4 Cerebellum: 20.3 ± 2.6 4	rhaboid nucleus	62.7 ± 11.4	4
substantia nigra 48.5 ± 13.2 4Cranial Nerve Nuclei: spinal trigeminal nuclei spinal trigeminal tract 55.3 ± 11.1 20.3 ± 2.6 4Pons: pontine nucleus locus coeruleus dorsal tegmental nuclei raphe points 42.4 ± 3.4 42.7 ± 12.2 37.4 ± 13.6 4Medulla Oblongata: nucleus solitary tract inferior olive 48.5 ± 9.5 53.7 ± 13.0 48.2 ± 4.4 4Cerebellum: Delivier 42.4 ± 3.4 42.7 ± 12.2 37.4 ± 13.6 4	interpeduncular nucleus	50.1 ± 9.1	4
Cranial Nerve Nuclei: spinal trigeminal nuclei spinal trigeminal tract 55.3 ± 11.1 20.3 ± 2.6 4Pons: pontine nucleus locus coeruleus dorsal tegmental nuclei raphe points 42.4 ± 3.4 42.7 ± 12.2 37.4 ± 13.6 4Medulla Oblongata: nucleus solitary tract brainstem reticular nucleus inferior olive 48.5 ± 9.5 53.7 ± 13.0 48.2 ± 4.4 4	substantia nigra	48.5 ± 13.2	4
Cranial Nerve Nuclei: spinal trigeminal nuclei 55.3 ± 11.1 4spinal trigeminal ract 20.3 ± 2.6 4Pons: pontine nucleus locus coeruleus 42.4 ± 3.4 4locus coeruleus dorsal tegmental nuclei 42.7 ± 12.2 4raphe points 37.4 ± 13.6 4Medulla Oblongata: nucleus solitary tract inferior olive 48.5 ± 9.5 4Cerebellum: 53.7 ± 13.0 4			
spinal trigeminal nuclei 55.3 ± 11.1 4spinal trigeminal tract 20.3 ± 2.6 4Pons: 20.3 ± 2.6 4pontine nucleus 42.4 ± 3.4 4locus coeruleus 35.1 ± 3.4 4dorsal tegmental nuclei 42.7 ± 12.2 4raphe points 37.4 ± 13.6 4Medulla Oblongata: 48.5 ± 9.5 4inferior olive 48.2 ± 4.4 4Cerebellum: 42.4 ± 3.4 4	Cranial Nerve Nuclei:		
spinal trigeminal tract 20.3 ± 2.6 4Pons: pontine nucleus locus coeruleus dorsal tegmental nuclei raphe points 42.4 ± 3.4 42.7 ± 12.2 37.4 ± 13.6 4Medulla Oblongata: nucleus solitary tract brainstem reticular nucleus inferior olive 48.5 ± 9.5 53.7 ± 13.0 48.2 ± 4.4 4Cerebellum: Delitie with 41.4 ± 3.4 42.7 ± 3.4 42.7 ± 3.4 42.7 ± 3.4 41.4 ± 3.4 42.7 ± 3.4 42.7 ± 3.4 41.4 ± 3.4 42.7 ± 3.4	spinal trigeminal nuclei	55.3 \pm 11.1	4
Pons: 42.4 ± 3.4 4locus coeruleus 35.1 ± 3.4 4dorsal tegmental nuclei 42.7 ± 12.2 4raphe points 37.4 ± 13.6 4Medulla Oblongata: 48.5 ± 9.5 4brainstem reticular nucleus 53.7 ± 13.0 4inferior olive 48.2 ± 4.4 4	spinal trigeminal tract	20.3 ± 2.6	4
Point 42.4 ± 3.4 4 locus coeruleus 35.1 ± 3.4 4 dorsal tegmental nuclei 42.7 ± 12.2 4 raphe points 37.4 ± 13.6 4 Medulla Oblongata: 48.5 ± 9.5 4 nucleus solitary tract 48.5 ± 9.5 4 brainstem reticular nucleus 53.7 ± 13.0 4 inferior olive 48.2 ± 4.4 4	Pons		
Jocus coeruleus locus coeruleus dorsal tegmental nuclei raphe points 35.1 ± 3.4 42.7 ± 12.2 37.4 ± 13.6 4Medulla Oblongata: nucleus solitary tract brainstem reticular nucleus inferior olive 48.5 ± 9.5 53.7 ± 13.0 48.2 ± 4.4 4Cerebellum: Delivier When 42.7 ± 12.2 42.7 ± 12.2 44 4	pontine nucleus	121 + 31	4
Instance 33.1 ± 3.4 dorsal tegmental nuclei 42.7 ± 12.2 raphe points 37.4 ± 13.6 Medulla Oblongata: 48.5 ± 9.5 nucleus solitary tract 48.5 ± 9.5 brainstem reticular nucleus 53.7 ± 13.0 inferior olive 48.2 ± 4.4 Cerebellum:	locus coeruleus	42.4 ± 5.4 35.1 ± 3.4	4
raphe points 42.7 ± 12.2 raphe points 37.4 ± 13.6 Medulla Oblongata: nucleus solitary tract 48.5 ± 9.5 brainstem reticular nucleus inferior olive 53.7 ± 13.0 Cerebellum: Delivier with 48.2 ± 4.4	dorsal tegmental nuclei	33.1 ± 3.4	4
Medulla Oblongata: nucleus solitary tract brainstem reticular nucleus inferior olive 37.4 ± 13.0 48.5 ± 9.5 53.7 ± 13.0 48.2 ± 4.4 Cerebellum: Delivier 48.2 ± 4.4	raphe points	42.7 ± 12.2	4
Medulla Oblongata: nucleus solitary tract brainstem reticular nucleus inferior olive 48.5 ± 9.5 53.7 ± 13.0 48.2 ± 4.4 4Cerebellum: Delivier 48.2 ± 4.4 4		J7.4 ± 15.0	
nucleus solitary tract 48.5 ± 9.5 4brainstem reticular nucleus 53.7 ± 13.0 4inferior olive 48.2 ± 4.4 4Cerebellum:	Medulla Oblongata:		
brainstem reticular nucleus inferior olive <i>53.7 \pm 13.0 4 4 4 <i>4</i> <i>4</i> <i>4</i> <i>4</i> <i>4</i> <i>4</i> </i>	nucleus solitary tract	48.5 ± 9.5	4
inferior olive 48.2 ± 4.4 4 Cerebellum:	brainstem reticular nucleus	53.7 ± 13.0	4
Cerebellum:	inferior olive	48.2 ± 4.4	. 4
Cerebellum:			
	Cerebellum:		
Purkinje cell layer 64.0 ± 10.5 4	Purkinje cell layer	64.0 ± 10.5	4
granular cell layer 46.1 ± 7.5 4	granular cell layer	46.1 ± 7.5	4
molecular cell layer 23.4 ± 1.1 4	molecular cell layer	23.4 ± 1.1	4

	[³ H]-DM Bound (fmol/mg)		
Brain Area	contralateral	ipsilateral	n
Carala d Cara			
Cerebral Cortex:	20 4 1 7 1		
cingulate	32.4 ± 7.1	32.9 ± 7.0	5
	32.4 ± 7.9	32.6 ± 6.2	
	34.3 ± 6.2	36.2 ± 5.8	
Insular retrocological	25.5 ± 8.9	32.5 ± 6.6	5
	30.0 ± 8.9	26.5 ± 7.9	
	29.8 ± 9.6	31.7 ± 7.0	5
	35.0 ± 10.5	35.9 ± 7.7	5
perirninal	31.3 ± 9.6	28.6 ± 6.8	5
entorninal	27.6 ± 9.0	22.2 ± 7.1	2
Pagal Canalia			
busul Gunglia.	205172	21 4 1 6 0	5
nucleus soumbers	30.5 ± 7.2	31.4 ± 6.0	5
globus pollidus	31.4 ± 8.2	34.2 ± 8.1	5
globus pallidus	37.7 ± 7.7	36.5 ± 7.0	
Septum:			
lateral septal nucleus	22.1 ± 4.5	21.0 ± 4.8	5
Amvedala:			
basolateral amygdalioid nucleus	33.8 ± 8.5	34.4 ± 6.9	5
Hippocampus			
CA1	34.8 ± 7.1	37.4 ± 4.8	5
CA2	40.1 ± 7.6	40.9 ± 6.3	5
CA3	41.1 ± 7.5	41.8 ± 6.7	5
dentate gyrus	35.7 ± 7.7	34.1 ± 7.0	5
Thalamus:			
laterodorsal thalamus	44.1 ± 8.7	43.9 ± 8.2	5
mediodorsal thalamus	46.7 ± 8.6	46.7 ± 8.9	5
ventral thalamus	42.1 ± 8.6	43.7 ± 8.2	5
geniculate nucleus	42.7 ± 8.9	41.5 ± 9.3	5
Hypothalamus			.
ventromedial hypothalamus	39.8 + 5.6	40.8 ± 6.4	5
	1		1 1

TABLE 2: Autoradiographical distribution of [³H]-DM binding sites in the sham-operated rat brain.

TABLE 2 (continued)

Brain Area	[³ H]-DM Bound (fmol/mg)	n
Midbrain:		· .
central grey	35.8 ± 7.9	5
caudal linear raphe nucleus	36.8 ± 10.1	5
dorsal raphe nucleus	47.8 ± 9.3	5
median raphe nucleus	33.7 ± 7.4	5
rhaboid nucleus	42.8 ± 7.1	5
Medulla Oblongata: nucleus solitary tract reticular nucleus	36.8 ± 7.1 36.6 ± 7.6	5 5
Cerebellum:		
Purkinje cell layer	48.6 ± 10.3	5
granular cell layer	28.6 ± 7.8	5
molecular cell layer	15.4 ± 4.4	5

	[³ H]-DM Bound (fmol/mg)		
Brain Area	contralateral	ipsilateral	n
Cerebral Cortex:	440.00		
cingulate	44.9 ± 8.5	43.1 ± 8.7	5
frontal	42.7 ± 7.3	35.2 ± 8.5	5
parietal	43.1 ± 7.8	21.8 ± 6.4	5
insular	33.9 ± 5.8	29.7 ± 8.4	
retrosplenial	32.5 ± 7.3	32.5 ± 7.4)
occipital	26.1 ± 7.8	17.4 ± 3.6	5
temporal	28.8 ± 9.0	20.2 ± 4.1	5
perirhinal	22.0 ± 5.2	22.4 ± 3.3	2
entorhinal	22.4 ± 6.0	26.2 ± 3.3	5
Basal Ganglia:			
caudate putamen	43.9 ± 8.1	41.4 ± 8.7	5
nucleus acumbens	37.8 ± 35.1	35.1 ± 8.4	5
globus pallidus	34.9 ± 2.5	36.3 ± 2.9	5
Septum:			
lateral septal nucleus	34.0 ± 6.9	34.7 ± 6.3	5
Amvodala			
basolateral amygdalioid nucleus	20.6 ± 7.2	22.5 ± 5.6	5
Hippocampus			
CA1	23.3 ± 6.0	26.9 ± 6.5	5
CA2	28.8 ± 6.9	34.9 ± 7.8	5
CA3	30.3 ± 8.2	33.9 ± 8.0	5
dentate gyrus	30.8 ± 36.2	36.2 ± 3.7	5
Thalamus			
laterodoreal thalamus	328 ± 10.7	35.0 ± 9.6	5
mediodorsal thalamus	32.0 ± 10.7 21.0 ± 0.2	32.9 + 8.8	5
methodolsal malamus	51.8 ± 8.2	32.7 ± 0.0 33.6 ± 10.0	5
venuar maianius	32.9 ± 8.8	55.0 ± 10.0 51 3 + 7 7	5
geniculate nucleus	43.5 ± 9.7	51.5 - 1.1	5
Hypothalamus:			
ventromedial hypothalamus	26.6 ± 8.1	30.9 ± 8.1	5
			1 1

TABLE 3:Autoradiographical distribution of [³H]-DM binding sites in the
MCA-occluded rat brain

TABLE 3 (continued)

Brain Area	[³ H]-DM Bound (fmol/mg)	n
Midbrain: central grey caudal linear ranke nucleus	39.1 ± 4.0 46.7 ± 4.3	5
dorsal raphe nucleus median raphe nucleus rhaboid nucleus	$47.5 \pm 4.1 \\ 41.5 \pm 5.2 \\ 45.5 \pm 4.1$	5 5 5 5
Medulla Oblongata: nucleus solitary tract reticular nucleus	32.7 ± 7.4 34.7 ± 6.8	5 5
Cerebellum: Purkinje cell layer granular cell layer molecular cell layer	43.0 ± 7.4 23.0 ± 7.3 14.0 ± 4.4	5 5 5





FIGURE 2



FIGURE 3



FIGURE 4



